tetano
Editor, Senior Moderator
Exp Hematol
. 2021 Dec 21;S0301-472X(21)00855-9.
doi: 10.1016/j.exphem.2021.12.396. Online ahead of print.
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment
Ariella Tvito[SUP] 1 [/SUP], Aaron Ronson[SUP] 2 [/SUP], Renan Ghosheh[SUP] 2 [/SUP], Mira Kharit[SUP] 2 [/SUP], Jakob Ashkenazi[SUP] 2 [/SUP], Sophie Magen[SUP] 3 [/SUP], Ellen Broide[SUP] 3 [/SUP], Emmanuel Benayoun[SUP] 3 [/SUP], Jacob M Rowe[SUP] 2 [/SUP], Yishai Ofran[SUP] 2 [/SUP], Chezi Ganzel[SUP] 2 [/SUP]
Affiliations
Abstract
The Covid-19 pandemic caused millions of death worldwide. Vaccines have been developed but patients on immunosuppressive therapy are less likely to respond. This study aimed to investigate the efficacy of Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma, treated with anti-CD20 monoclonal antibodies. Only one of 28 lymphoma patients (3.6%) developed a seropositive response compared to 100% (28 of 28) of the healthy volunteers. The low levels of CD19+ lymphocytes among the lymphoma patients suggest that the anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients, once B cells are repopulated.
Keywords: Covid-19; Non Hodgkin lymphoma; Pfizer-BioNTech; anti-CD20; coronavirus; monoclonal antibodies; rituximab; vaccination.
. 2021 Dec 21;S0301-472X(21)00855-9.
doi: 10.1016/j.exphem.2021.12.396. Online ahead of print.
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment
Ariella Tvito[SUP] 1 [/SUP], Aaron Ronson[SUP] 2 [/SUP], Renan Ghosheh[SUP] 2 [/SUP], Mira Kharit[SUP] 2 [/SUP], Jakob Ashkenazi[SUP] 2 [/SUP], Sophie Magen[SUP] 3 [/SUP], Ellen Broide[SUP] 3 [/SUP], Emmanuel Benayoun[SUP] 3 [/SUP], Jacob M Rowe[SUP] 2 [/SUP], Yishai Ofran[SUP] 2 [/SUP], Chezi Ganzel[SUP] 2 [/SUP]
Affiliations
- PMID: 34952139
- DOI: 10.1016/j.exphem.2021.12.396
Abstract
The Covid-19 pandemic caused millions of death worldwide. Vaccines have been developed but patients on immunosuppressive therapy are less likely to respond. This study aimed to investigate the efficacy of Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma, treated with anti-CD20 monoclonal antibodies. Only one of 28 lymphoma patients (3.6%) developed a seropositive response compared to 100% (28 of 28) of the healthy volunteers. The low levels of CD19+ lymphocytes among the lymphoma patients suggest that the anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients, once B cells are repopulated.
Keywords: Covid-19; Non Hodgkin lymphoma; Pfizer-BioNTech; anti-CD20; coronavirus; monoclonal antibodies; rituximab; vaccination.